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Background: Incomplete spontaneous abortions are defined by the intrauterine retention of the products of
conception after their incomplete or partial expulsion. This condition may be managed by expectant care, medical
treatment or surgery. Vacuum aspiration is currently the standard surgical treatment in most centers. However,
operative hysteroscopy has the advantage over vacuum aspiration of allowing the direct visualization of the
retained conception product, facilitating its elective removal while limiting surgical complications. Inadequately
powered retrospective studies reported subsequent fertility to be higher in patients treated by operative
hysteroscopy than in those treated by vacuum aspiration. These data require confirmation in a randomized
controlled trial comparing fertility rates between women undergoing hysteroscopy and those undergoing vacuum
aspiration for incomplete spontaneous abortion.
Methods: After providing written informed consent, 572 women with incomplete spontaneous abortion recruited
from 15 centers across France will undergo randomization by a centralized computer system for treatment by
either vacuum aspiration or operative hysteroscopy. Patients will not be informed of the type of treatment that
they receive and will be cared for during their hospital stay in accordance with standard practices at each center.
The patients will be monitored for pregnancy or adverse effects by a telephone conversation or questionnaire sent
by e-mail or post over a period of two years. In cases of complications, failure of the intervention or diagnosis of
uterine cavity disease, patient care will be left to the discretion of the medical center team.
Discussion: If our hypothesis is confirmed, this study will provide evidence that the use of operative hysteroscopy
can increase the number of pregnancies continuing beyond 22 weeks of gestation in the two-year period following
incomplete spontaneous abortion without increasing the incidence of morbidity and peri- and postoperative
complications. The standard surgical treatment of this condition would thus be modified. This study would
therefore have a large effect on the surgical management of incomplete spontaneous abortion.
Trial registration: ClinicalTrials.gov Identifier: NCT02201732; registered on 17 July 2014.
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Incomplete spontaneous abortions are defined as the
intrauterine retention of the products of conception
after non-discharge or partial discharge of the egg. After
miscarriage, 60 % of women wishing to fall pregnant
again are able to do so within 2 years, and 80 % after
5 years [1].
Intrauterine retention after miscarriage is treated by
expectant or medical management or surgery [2, 3]. Sur-
gical treatment may be performed immediately or fol-
lowing the failure of expectant or medical treatment.
Vacuum aspiration is currently the standard surgical
treatment in most centers. However, it is typically car-
ried out in a blind manner, and can therefore lead to the
persistence of intrauterine retention, which may not be
diagnosed initially. This persistence may be complicated
by chronic infection and may require further surgical
intervention. The abrasion of the uterine lining that oc-
curs during this blind procedure can also cause simple
or complex intrauterine adhesions. The prevalence of
these adhesions is around 20 % after curettage for spon-
taneous abortion [4, 6] and 40 % for repeat procedures
[7]. Such adhesions, like chronic endometritis resulting
from persistent retention after curettage, may be detri-
mental to subsequent fertility and require further surgi-
cal intervention.
Some studies have reported that hysteroscopy is a
beneficial surgical treatment for intrauterine retention
after miscarriage, with treated women falling pregnant
again within 2 years of the initial intervention in
more than 70 % of cases [7, 8]. Hysteroscopy makes
it possible to visualize the retention product, its elect-
ive removal and the integrity of the cavity directly,
without trauma to the adjacent endometrium, while
limiting the complications of surgery and the number
of repeat interventions due to retention or adhesions,
as indicated in a systematic review that retrieved a
low frequency of intrauterine adhesions (5.7 %) after
the hysteroscopic removal of retained products of
conception [9]. Furthermore, hysteroscopy may facili-
tate the diagnosis of abnormalities or diseases of the
uterine cavity (fibroids, polyps), which may be respon-
sible for spontaneous abortions. These abnormalities
may be amenable to surgical treatment, improving the
management of patients and their prognosis in terms
of fertility.
Two retrospective studies have compared the effect-
iveness of hysteroscopy and curettage for the manage-
ment of post-abortion and postpartum retention [10,
11]. The first study compared 24 women who un-
derwent curettage with 46 women who underwent
hysteroscopic resection. Overall, 20 % of women in the
curettage group required secondary hysteroscopy to
empty the uterus, whereas no further surgery was requiredin the hysteroscopy group [10]. Furthermore, the women
in the hysteroscopy group fell pregnant more quickly after
the intervention than those in the curettage group. The
second study, based on a before/after design, compared 42
women who underwent ultrasound-guided curettage with
53 women who underwent hysteroscopy [11]; these 95
women corresponded to 88 cases of failed curettage after
miscarriage and seven cases of postpartum retention of
the placenta after cesarean section. This study also found
that the mean time to conception was shorter among
women wishing to fall pregnant again in the hysteroscopy
group than in those of the curettage group. Furthermore,
despite preliminary curettage in cases of trophoblastic re-
tention, this study also reported that the rate of pregnancy
was significantly higher in the hysteroscopy group than in
the curettage group (69 % vs 60 %, respectively). Pooling
these two studies in a meta-analysis, Smorgick et al. ob-
tained an odds ratio of 1.7 (95 % CI 0.7–3.8, p = 0.1) for
pregnancy in the hysteroscopy group, with the curettage
group used as the reference group [9]. These results pro-
vide support for the idea that incomplete spontaneous
abortions can be managed by hysteroscopy. However,
the retrospective design of these studies, the hetero-
geneity of the patients included and the low power
are such that it is not possible to determine whether
hysteroscopy is the best treatment option for intrauterine
retention. A randomized, controlled trial is required to
evaluate the place of hysteroscopy among the various
treatment options.
The main objective of our study is to compare fertility
rates between women undergoing hysteroscopy and
those undergoing vacuum aspiration for intrauterine re-
tention following miscarriage, in a pragmatic approach.
The secondary objectives of the study are: (1) to com-
pare times to conception following the two surgical
treatments and (2) to investigate whether hysteroscopy
is associated with fewer peri- and postoperative compli-
cations and repeat procedures.Methods
Items from the World Health Organization Trial Regis-
tration Data Set for the Operative hysteroscopy versus
vacuum aspiration for incomplete spontaneous abortion
(HY-PER) trial are shown in Additional file 1. The TIDieR
(Template for Intervention Description and Replication)
and SPIRIT (Standard Protocol Items: Recommendations
for Interventional Trials) 2013 Checklists are presented in
Additional files 2 and 3.Study design
The HY-PER trial is a randomized, open, multicenter
trial comparing vacuum aspiration with hysteroscopy in
women with incomplete spontaneous abortion.
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Protocol version 1.1 for this study, dated 06/16/2014, was
approved by the “Comité de Protection des Personnes”
(CPP) Ile de France XI (no. 14040) and the ANSM
(no. 140516B-22). Modified protocol version 2.1 dated
5 June 2015 was approved by the CPP Ile de France
XI (no. 14040) on 6 November 2015. Any further
modification of the protocol will require approval
from the CPP and will be communicated to the local
investigators.
Main outcome
The main outcome is intrauterine pregnancy lasting up
to least 22 weeks of gestation in the 2 years after the
management of incomplete spontaneous abortion.
Secondary outcomes
The secondary outcomes are as follows: time to con-
ception; pregnancy outcome: incidence of miscarriage
and ectopic pregnancy during the two-year follow-up
period; number of surgical complications according to
the Clavien-Dindo classification [12]; and the incidence of
secondary surgical interventions for the management of
intrauterine retention after miscarriage.
Recruitment
Patients will be recruited from 15 centers (general and
university hospitals) throughout France: Centre Hospitalier
Intercommunal de Poissy-St-Germain en Laye, Poissy;
Hôpital Bichat (AP-HP), Paris; Hôpital La Conception
(AP-HM), Marseille; Strasbourg University Hospital,
Strasbourg; CHR Orléans, Orléans; Rennes University
Hospital, Rennes; CHU Estaing, Clermont Ferrand;
Hôpital Bicêtre (AP-HP), Le Kremlin Bicêtre; CHU de
Poitiers, Poitiers; Hôpital Alix de Champagne, Reims;
CHU d’Angers, Angers; Hôpital Jeanne-de-Flandre,
Lille; Centre Hospitalier Intercommunal de Villeneuve-
Saint-Georges, Villeneuve-Saint-Georges; Centre hospita-
lier de Versailles, Le Chesnay; and Hôpital Louis Mourier
(AP-HP), Colombes. The inclusion potential of each cen-
ter was determined from the number of deliveries per year
at the center concerned.
Inclusion criteria
The women included in this study will have the following
characteristics:
 between the ages of 18 and 44 years, covered
by the social security system and presenting
with trophoblastic intrauterine retention
following incomplete spontaneous abortion
after the first trimester (<14 weeks of amenorrhea)
 the pregnancy concerned should correspond to a
planned/wanted baby diagnosis of intrauterine retention by transvaginal
pelvic ultrasound showing a heterogeneous
intrauterine mass or an intrauterine sac over
15 mm thick, with or without endometritis
 selected by the medical team for surgical
management on the basis of local management
protocols
 written consent provided.
Exclusion criteria
The exclusion criteria are as follows:
 known uterine malformations
 history of surgical treatment for intrauterine
retention
 intrauterine retention of material over 50 mm thick,
diagnosed by transvaginal pelvic ultrasound
 emergency hemostatic therapy to treat heavy vaginal
bleeding (hemorrhagic miscarriage)
 presence of an intrauterine device
 ongoing pregnancy
 extra uterine pregnancy
 trophoblastic retention following an abortion;
 pregnancy obtained by medically assisted
procreation.
Interventions
The design of the study is summarized in a schematic
diagram and a patient flow chart (Fig. 1 and Table 1).
The interventions to be evaluated are operative hyster-
oscopy (arm A) and vacuum aspiration (arm B) for the
management of incomplete spontaneous abortions. These
procedures are routinely performed in the participating
centers, for various indications, by the local investigators.
For both surgical procedures, surgical antibiotic prophy-
laxis, misoprostol to dilate the cervix, and anti-adhesion
barrier gels will be used, according to the routine proce-
dures of each center. In cases of intrauterine retention
complicated by endometritis, antibiotic treatment for
48 hours (penicillin, metronidazole, fluoroquinolones or a
combination of these antibiotics) will be administered
according to the standard practice of each center. The
evacuated retention product will be sent for pathological
examination. Rhesus-negative women will receive prophy-
laxis to prevent Rh alloimmunization.
Arm A: operative hysteroscopy
Operative hysteroscopy is a routine surgical procedure
for the management of intrauterine disease in obstetrics
and gynecology departments. The procedure will be per-
formed by a gynecological surgeon, under general or
local anesthesia, according to the standard practice of the
center concerned, with the patient in the gynecological
position. Antibiotic prophylaxis may be administered,
Fig. 1 Patient flow chart
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vix is grasped with pozzi forceps and dilated, with up to a
size-9 Hegar dilator if necessary, to facilitate insertion of
the hysteroscope. The equipment available at the center
will be used for operative hysteroscopy. The uterine cavity
will be distended with saline or glycine, depending on the
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endometrium in previous studies [7, 8]. The use of forceps
or curettes to facilitate the removal of material is permit-
ted. An electrical current will be used only as a last resort,
in cases in which the retained conception product cannot
be removed without it. If active bleeding occurs after
surgery, elective coagulation via the hysteroscope may
be carried out to stop intrauterine bleeding. The dis-
tension medium will be measured and examined on
entry and exit.
Arm B: vacuum aspiration
Vacuum aspiration will be carried out by a gynecological
surgeon, according to the standard protocol of the cen-
ter. A flexible or rigid vacurette may be used. Antibiotic
prophylaxis, the diameter of the vacurette used, the
extent of cervical dilatation necessary and the use of
intraoperative ultrasound guidance will be left to the
discretion of the operator and the standard practice of
the center. In most centers, the cervix is dilated with a
size-9 Hegar dilator for vacuum aspiration. In some
centers, the expansion is minimized (in practice, Hegar
dilator size 7) to limit the risk of subsequent preterm
birth. However, published studies have not reported
any benefits of moderate over maximal cervical dila-
tion. The participating centers will therefore be free
to carry out cervical dilation according to their stand-
ard practices and to use the size and type of vacur-
ette of their choice. In arm A, the use of forceps or
curettes to facilitate the removal of material is permitted
during the procedure. The scoop of the curette is
usually examined to ensure that the uterus is empty
at the end of curettage and this practice will be authorized
in this trial.
Examination on inclusion
The initial assessment will include a complete gyne-
cological examination. The patient’s hemodynamic vari-
ables (heart rate, blood pressure, temperature) will be
recorded and signs of shock sought, to identify women
susceptible to hemorrhagic shock in cases of heavy
bleeding (exclusion criterion). The last menstrual period
of the patient and/or the exact start date of pregnancy in
cases in which the pregnancy was dated by early pelvic
ultrasound will be recorded. The pelvic examination
should include (1) a speculum examination to search for
bleeding and to evaluate its extent and source and (2) a
vaginal examination to assess pain originating in the
uterus or elsewhere.
Incomplete spontaneous abortion will be diagnosed by
transvaginal ultrasound performed according to a previ-
ously published standard technique for pelvic ultrasound
[13]. It must include the median sagittal section of
the uterus passing through the endocervical cavity and asection centered on the uterine cavity and passing through
the thickest part of the retained conception product, the
dimensions of which will be measured. Intrauterine reten-
tion will be diagnosed on the basis of the visualization of a
heterogeneous intrauterine mass or an intrauterine sac
over 15 mm thick.
An ultrasound scan showing a visible intrauterine
pregnancy before the expulsion will be required to con-
firm the intrauterine nature of the pregnancy and to ex-
clude extra-uterine pregnancies. If the intrauterine nature
of the pregnancy or its stage cannot be confirmed, β
human chorionic gonadotropin (βhCG) levels will be
analyzed over 48 hours. A 50 % decrease in βhCG levels
over 48 hours will be considered to confirm that the
interrupted pregnancy was indeed intrauterine [14].
The intrauterine nature of the pregnancy will be further
confirmed by histological analysis of the retained concep-
tion product.
Women experiencing hyperthermia or pelvic pain will
be examined for endometritis, which may occur as a
complication of incomplete miscarriage. Endometritis
will be diagnosed according to the criteria in the 2012
guidelines for clinical practice from the French National
College of Obstetricians-Gynecologists [15]: the pres-
ence of pain following uterine mobilization associated
with hyperthermia or high C-reactive protein (CRP) levels,
a positive vaginal swab or signs of endometritis on endo-
metrial biopsy. If the blood group of the patient is un-
known, rhesus status will be determined and prophylaxis
for Rh alloimmunization will be initiated if the patient is
Rh-negative.
During this visit, the patient will complete a self-
administered questionnaire on her medical history and
the lost pregnancy. Details of the protocol will be pro-
vided to the patient through a written notice and oral
explanations. Signed consent forms will be collected
from patients agreeing to participate in the study prior
to enrollment, by a senior gynecologist acting as a local
investigator in the trial. Informed consent form is shown
in Additional file 4.
Randomization
After the patient has been informed, written informed
consent obtained and the criteria for inclusion and exclu-
sion have been checked, a single-blind randomization with
a 1:1 ratio will be performed electronically with a secure
internet platform, on arrival in the operating room.
The patient will not be informed of the procedure
that she has undergone. In addition, the operating
rooms will be systematically prepared for hysteros-
copy, so that the patient cannot guess the nature of
the procedure performed. The intervention will be
unblinded if patients experience adverse effects during
the study period.
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During their stay in hospital, the patients will be man-
aged according to the standard practice of the center. A
standardized surgical report will be given to patients
included in the study, with no mention of the type of
surgical procedure. The patient will then receive a de-
tailed surgical report at the end of her participation in
the trial.
Postoperative consultation
Patients will attend a postoperative consultation within
three to eight weeks of the intervention, to check for the
absence of complications following the procedure and
exposure to pregnancy. Postoperative management, in
terms of monitoring, is identical for curettage and hys-
teroscopy; it should therefore be possible to maintain
the single-blind design. If a procedure or special assess-
ment needs to be carried out according to the standard
practice of the center (assessment of spontaneous abor-
tion, pelvic ultrasound, diagnostic hysteroscopy) it will
be performed without compromising the single-blinded
nature of the study. According to amendment of the
protocol v2.1 dated 6 May 2015, patients may also be
contacted by phone if they do not attend the postopera-
tive consultation, to check for the absence of adverse
effects.
Follow up
After their initial postoperative consultation, patients
will attend follow up 6 months, one year and 2 years
after surgical treatment or until the successful com-
pletion of a subsequent pregnancy. Thus, the length of
participation of each patient starts from their inclusion
in the study, lasting until subsequent childbirth, or a
maximum of 2 years. Each patient will be contacted by
telephone. In the absence of a reply, an email and/or a
letter will be sent. Subsequent pregnancies, surgical pro-
cedures and gynecological findings, such as the diagnosis
of abnormal intrauterine pathology (by diagnostic hyster-
oscopy, hysterosonography, hysterography or pelvic ultra-
sound) will be recorded. Women will be asked about their
exposure to pregnancy (sexual intercourse without con-
traception), and their use of medical procedures for pro-
creation. The dates of the beginning and the end of any
subsequent pregnancies (miscarriage, abortion, ectopic
pregnancy, childbirth) will be recorded. The blinding of
the study will be assessed during interviews with the pa-
tients during follow up. Patients may reply that (1) they
do not know which arm they were assigned to, (ii) they
think they underwent hysteroscopy, or (iii) they think they
underwent vacuum aspiration.
The primary endpoint of the trial is a pregnancy of at
least 22 weeks duration in the 2 years of follow up. The
progress of the pregnancy will be evaluated according tostandard procedures. These data will be collected
from a standardized report of the pregnancy and birth
(see Additional file 5). In cases of delivery at the same
hospital or of additional examinations or surgical pro-
cedures, medical records may be used to complete the
information.
Sample size
The mean live birth rate at 2 years after intrauterine
retention following miscarriage is 60 % [1]. To demon-
strate that the use of hysteroscopy increases this rate by
20 %, i.e., to 72 % with a power of 80 % and α = 0.05
(two-tailed), the number of patients required for this study
is 520 (260 per arm) [16, 17]. Assuming that 10 % of pa-
tients in each group will be lost to follow up, we plan to
include 286 patients in each arm, or 572 patients in total.
Handling of missing data
Participants lost to follow up will be taken into account
on the basis of their last known status and several re-
minders will be sent. We will check that the participants
lost to follow up are equally distributed between the two
arms of the trial, which is the usual procedure to deal
with such participants in this type of trial. An explanatory
calculation may be performed to classify these participants
as failures (no pregnancy of more than 22 weeks of gesta-
tion within 2 years). Methods based on multiple imput-
ation may also be used.
Statistical analysis
The intention-to-treat principle will be used during stat-
istical analysis; thus, the analysis will be performed on
the final list of all randomized patients included in the
trial. The main outcome measure will be a comparison
between the two arms of the proportion of patients with
a pregnancy lasting for more than 22 weeks gestation in
the 2 years of follow up, based on the chi-squared test.
Multiple pregnancies (i.e., twin pregnancy outcome: inci-
dence of miscarriage and ectopic pregnancy during the
2-year follow-up period or more) will be counted as a
single pregnancy lasting for at least 22 weeks of gesta-
tion in this comparison.
A secondary analysis will be performed by the Kaplan-
Meier method [18]. The event considered for time-to-
event analyses will be the occurrence of a pregnancy
lasting for at least 22 weeks, with measured exposure to
pregnancy (desire to become pregnant, with no use of
contraception). In the time-to-event analyses, patients
with a successful pregnancy will be counted as successful
outcomes and will then be censored. No other pregnancy
in the 2 years of follow up will be taken into account for
these patients. By contrast, the event of interest will not
be considered to have occurred in patients experiencing a
loss of the pregnancy before 22 weeks of gestation and
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pregnancy lasting at least 22 weeks is achieved. In this
analysis, the log-rank test will be used to compare concep-
tion rates between the two randomization groups [19].
Cox proportional hazards regression [20] will be used to
take into account possible confounding factors. We also
will estimate the probability of conception after treatment,
by measuring monthly fertility and its 95 % confidence
interval from the number of spontaneous conceptions per
person per month of follow up. Secondary endpoints
(incidence of miscarriage and ectopic pregnancy in the
2-year follow-up period; surgical complications accord-
ing to the Clavien-Dindo classification; secondary surgical
intervention for the management of intrauterine retention
after miscarriage) will be analyzed and compared between
the two arms by chi-squared test. All tests will be two-
tailed. Interim analyses are not planned. Stata version 13
software (Stata Corp., College Station, TX, USA) will be
used for all statistical analyses.
Data collection and management
Data for all phases of the study will be collected in a step-
wise manner using the secure online internet platform,
Cleanweb (https://cleanweb.aphp.fr/Ctms-02/portal/login).
Personal information relating to the participants enrolled
will be known only to the local investigators. The first letter
of the given name and the first letter of the last name, to-
gether with the month and year of birth, will be collected
for each patient, to protect confidentiality in the database.
As neither the investigators nor the sponsor have any
competing interests and the study does not focus on the
use of drugs, no data monitoring committee is required.
Data quality will be monitored by visits to the investigat-
ing centers, with a frequency corresponding to the
planned follow up of patients in the protocol, inclusions
at the various centers and the level of risk attributed to
the protocol.
During subsequent visits, the observations will be
reviewed as the study progresses, by clinical research as-
sistants, who will be responsible for checking that the
data are correctly entered and for validating the data.
The principal investigator at each center and the other
investigators responsible for including or following up
subjects participating in the study will agree to visits
from representatives of the promoter, nominated by As-
sistance Publique-Hôpitaux de Paris (AP-HP), at regular
intervals. During these site visits, in accordance with
good clinical practice, the following aspects will be
audited:
 respect for the research protocols and the
procedures defined in it
 examination of the source documents, comparing
them with the data reported in the onlineobservation notebook, to assure the quality
of the results obtained: exactness, missing data,
data consistency.
Responsibility
AP-HP is the promoter for this study. In accordance
with biomedical research law, AP-HP has taken out an
insurance policy with GERLING KonZern for the entire
duration of the study, covering its own civil responsibility
and that of all those involved in the study (doctors and
staff involved in carrying out the research; law no. 2004–
806, Art. L.1121-10 of the CSP).
Publication and ownership of the results
AP-HP is the owner of all the data obtained, and no use
or transmission of these data to a third party is permit-
ted without prior agreement. The individuals who made
a genuine contribution to the development and running
of the protocol and to the writing up of the results will
be the first authors on any resulting publications. The
principal investigator and methodologists will be authors
on the principal publication. The positions of the inter-
mediate authors will depend on the number of patients
included and participation in the writing of the manu-
script (including participation in study design, data ana-
lysis and the writing and reviewing of the manuscript).
Discussion
This study is a single-blind randomized controlled trial.
The single-blind design was chosen so as to restrict any
placebo effect on the occurrence of pregnancy. A
double-blind design was not possible because the two
arms of the study correspond to surgical interventions.
Blinding for the patient will be assessed during follow
up, to determine the efficacy of the patient blinding
procedure.
The validity and reliability of data collection proce-
dures used in the trial could be called into question as
follow up is planned to involve telephone conversations
or questionnaires sent by email or post during a 2-year
period, rather than a review of medical records. How-
ever, patients often move house just before or after giv-
ing birth. The patient might then give birth at another
hospital and would be lost to follow up. In cases of
delivery at the same hospital, medical records could be
used to complete the information. Moreover, we took a
loss-to-follow-up rate of 10 % into account when deter-
mining sample size.
If our study provides evidence that the use of operative
hysteroscopy can increase the number of live births in
the two-year period following incomplete spontaneous
abortion without increasing the incidence of morbidity
and perioperative and postoperative complications, then
there will be a change in the standard surgical treatment
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impact on the surgical management of incomplete spon-
taneous abortion.
Trial status
The HY-PER trial is currently in the recruitment phase.
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